A new trading day began on Monday, with Taysha Gene Therapies Inc (NASDAQ: TSHA) stock price down -12.42% from the previous day of trading, before settling in for the closing price of $1.53. TSHA’s price has ranged from $1.27 to $4.32 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 129.39% over the past five years. Meanwhile, its annual earnings per share averaged 61.69%. With a float of $158.49 million, this company’s outstanding shares have now reached $186.96 million.
Let’s look at the performance matrix of the company that is accounted for 52 employees. In terms of profitability, gross margin is 89.73%, operating margin of -603.4%, and the pretax margin is -888.18%.
Taysha Gene Therapies Inc (TSHA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Taysha Gene Therapies Inc is 22.67%, while institutional ownership is 72.75%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares. Before that another transaction happened on Nov 17 ’23, when Company’s 10% Owner bought 100,000 for $1.63, making the entire transaction worth $163,000. This insider now owns 16,566,667 shares in total.
Taysha Gene Therapies Inc (TSHA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 61.69% per share during the next fiscal year.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Here are Taysha Gene Therapies Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.32.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.87, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Taysha Gene Therapies Inc (NASDAQ: TSHA) saw its 5-day average volume 3.85 million, a positive change from its year-to-date volume of 2.31 million. As of the previous 9 days, the stock’s Stochastic %D was 1.71%. Additionally, its Average True Range was 0.11.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 0.17%, which indicates a significant decrease from 0.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.72% in the past 14 days, which was lower than the 86.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0384, while its 200-day Moving Average is $2.3874. Nevertheless, the first resistance level for the watch stands at $1.4950 in the near term. At $1.6500, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7300. If the price goes on to break the first support level at $1.2600, it is likely to go to the next support level at $1.1800. Assuming the price breaks the second support level, the third support level stands at $1.0250.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
With a market capitalization of 248.62 million, the company has a total of 204,943K Shares Outstanding. Currently, annual sales are 15,450 K while annual income is -111,570 K. The company’s previous quarter sales were 1,110 K while its latest quarter income was -20,930 K.
